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Abstract 
The trend to inform personalized molecular radiotherapy with molecular imaging diagnostics, a concept 
referred to as theranostics, has transformed the field of nuclear medicine in recent years. The 
development of theranostic pairs comprising somatostatin receptor (SSTR)-targeting nuclear imaging 
probes and therapeutic agents for the treatment of patients with neuroendocrine tumors (NETs) has 
been a driving force behind this development. With the Neuroendocrine Tumor Therapy (NETTER-1) 
phase 3 trial reporting encouraging results in the treatment of well-differentiated, metastatic midgut 
NETs, peptide radioligand therapy (RLT) with the 177Lu-labeled somatostatin analog (SSA) 
[177Lu]Lu-DOTA-TATE is now anticipated to become the standard of care. On the diagnostics side, the 
field is currently dominated by 68Ga-labeled SSAs for the molecular imaging of NETs with positron 
emission tomography-computed tomography (PET/CT). PET/CT imaging with SSAs such as 
[68Ga]Ga-DOTA-TATE, [68Ga]Ga-DOTA-TOC, and [68Ga]Ga-DOTA-NOC allows for NET staging with 
high accuracy and is used to qualify patients for RLT. Driven by the demand for PET/CT imaging of NETs, 
a commercial kit for the production of [68Ga]Ga-DOTA-TATE (NETSPOT) was approved by the U.S. 
Food and Drug Administration (FDA). The synthesis of 68Ga-labeled SSAs from a 68Ge/68Ga-generator is 
straightforward and allows for a decentralized production, but there are economic and logistic difficulties 
associated with these approaches that warrant the search for a viable, generator-independent alternative. 
The clinical introduction of an 18F-labeled SSTR-imaging probe can help mitigate the shortcomings of the 
generator-based synthesis approach, but despite extensive research efforts, none of the proposed 
18F-labeled SSAs has been translated past prospective first-in-humans studies so far. Here, we review the 
current state of probe-development from a translational viewpoint and make a case for a clinically viable, 
18F-labeled alternative to the current standard [68Ga]Ga-DOTA-TATE. 
Key words: neuroendocrine tumors, SSTR2, 18F-Labeling, PET imaging 
Prolog 
The diagnostic arm of the theranostic approach 
to managing patients with neuroendocrine tumors 
(NETs) utilizes β+-emitter-labeled somatostatin recep-
tor (SSTR)-targeting ligands for tumor localization, 
staging, and therapy selection with positron emission 
tomography-computed tomography (PET/CT) [1]. 
With the FDA-approval of the commercial kit 
NETSPOT, [68Ga]Ga-DOTA-TATE has become the de 
facto standard for NET-imaging in the US [2]. The 
synthesis of [68Ga]Ga-DOTA-TATE from a 68Ge/ 
68Ga-generator is straightforward, reliable and allows 
for the decentralized production of the radionuclide 
and probe without the need of a cyclotron on site. A 
further advantage is that the identical chemical 
precursor can be used as the therapeutic companion 
when labeled with 177Lu or other therapeutic nuclides. 
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The simplicity of the 68Ga-labeling chemistry has 
likely been an important factor in helping several 
novel compounds advance through the clinical 
development cycle. 
Despite these merits, the generator-based 
approach holds certain economic and logistic 
difficulties that can hinder the widespread availability 
of NET scans. Smaller facilities with low patient 
throughput might struggle with the profitability of 
the generator (up to ~$ 100,000 USD per generator per 
year). Where demand is high, the probe production is 
complicated by the short half-life of 68Ga (68 min), and 
the low activity amounts that can be obtained from a 
single generator elution (typically 1.2 – 1.8 GBq from a 
fresh generator). Furthermore, driven by the 
introduction of the prostate cancer imaging probe 
68Ga-PSMA-11 and others [3], the popularity of 
68Ga-labeled imaging probes has sharply increased, 
such that the demand for 68Ga exceeds the supply. As 
a consequence, many facilities are now facing long 
waiting times to acquire 68Ge/68Ga-generators; a 
situation that is likely to be aggravated in the coming 
years. Although a method for the production of 68Ga 
from a cyclotron has been reported that could 
eventually address some of these issues, further 
process-validation and activity yield (AY) optimiz-
ation are needed to make this process clinically viable 
[4]. Notni and Wester have recently provided a 
comprehensive overview on supply and demand 
issues of various radioiosotopes [5]. The availability of 
an 18F-labeled, cyclotron-derived alternative to 
[68Ga]Ga-DOTA-TATE could help mitigate most of 
the challenges of generator-derived probe production. 
Large amounts of [18F]fluoride (typically 40 – 700 
GBq) can be produced at a comparably low cost, and a 
well-established distribution network of 18F-labeled 
probes is already in place [6]. 
Despite the many years spent developing 
18F-labeled SSAs, what prevents these probes from 
being used as a viable alternative to [68Ga]Ga- 
DOTA-TATE in the clinic? Following an introductory 
overview to 18F-labeled SSAs, the current state of 
probe development is reviewed. We emphasize the 
three main aspects that are relevant from a 
translational viewpoint: 1) Clinical suitability of the 
synthesis protocol, 2) Preclinical imaging perform-
ance, and 3) Validity of the probes as assessed in 
first-in-human studies.  
Introduction to 18F-Labeled SSAs 
SSTRs belong to the G-protein-coupled receptor 
family and are frequently upregulated in grade 1–2, 
well-differentiated NETs. Out of the five subtypes 
that have been evaluated (SSTR1-SSTR5), SSTR2 is 
predominantly overexpressed in these tumors, and 
SSTR2-targeting ligands have been the focus of 
attention in the last decades of probe development [7]. 
Most clinically used radioligands are derived from the 
octapeptide octreotide (Figure 1) which comprises a 
high affinity for SSTR2 (IC50 = 2.0 nM) and an 
appropriate elimination half-life (72 to 98 minutes) [8]. 
The first widely applied SSTR scintigraphy agent used 
in humans was the single-photon emission computed 
tomography (SPECT) probe 111In-diethylenetriamine-
pentaacetic acid-octreotide (OctreoScan) [9, 10]. Later, 
other octreotide derivatives like Tyr3-octreotide 
(TOC), Tyr3-octreotate (TATE), and 1-Nal3-octreotide 
(NOC) that bear a 1,4,7,10-tetraazacyclododecane- 
1,4,7,10-tetraacetic acid (DOTA)-chelated 68Ga-metal 
ion for PET/CT arrived on the scene and improved 
diagnosis and staging of NETs compared to the 
111In-labeled counterpart [11]. Among the technical 
advantages of PET/CT over SPECT are the higher 
spatial resolution and image quantification 
capabilities. This and the proven usefulness of 
68Ga-labeled SSAs in NET-theranostics [12] has 
triggered research aiming at the development of 
probes labeled with other β+-emitters such as 64Cu 
[13], 44Sc [14] and 18F. The focus of this review will lie 
on the latter since 18F is the most widely available 
PET-nuclide and its half-life (110 min), as 
well as low positron energy (maximum β+ 
energy = 635 keV), make it a close-to-ideal 
choice. More than 150 operating cyclotrons 
in the US ensure the availability of 
[18F]fluoride as well as 18F-labeled probes 
in a large area [6]. Although upfront costs 
for cyclotrons and the associated 
laboratory equipment are high (~$ 
1,000,000 – 3,000,000 USD), operating costs 
for the production of [18F]fluoride are 
comparably low and often financially 
supported by the distribution of high- 
demand probes like 2-deoxy-2-[18F]fluoro- 
D-glucose ([18F]FDG).  
 
 
Figure 1. Chemical structures of SSAs octreotide and octreotate. In octreotide, the C-terminal 
threonine (Thr) is reduced to the amino alcohol (yellow oval). Labeling moieties of all probes 
covered in this review are attached to the N-termini (red circles). In TOC and TATE, 
phenylalanine (Phe) of octreotide and octreotate (green ovals) are exchanged for tyrosine (Tyr). In 
NOC, Phe1 in octreotide (purple oval) is exchanged for naphthylalanine (Nal). 
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Seven different approaches to 18F-labeled SSAs 
have been described in the literature using a variety of 
synthetic strategies. Approach 1: Early efforts in the 
development of 18F-labeled SSAs by Guhlke et al. in 
1994 focused on [18F]fluoroacylation of octreotide 
analogs using the prosthetic group (±)-2-[18F] 
fluoropropionic acid-4-nitrophenyl ester ([18F]FP) [15, 
16]. Later, it was shown by Wester et al. that reducing 
the lipophilicity with the addition of carbohydrates 
improved the overall imaging performance [17-19]. 
Approach 2: A two-step process consisting of the 
synthesis of [18F]fluorobenzaldehyde ([18F]FBA) 
followed by labeling of the aminooxy-functionalized 
peptide was developed by Schottelius et al. [20, 21]. 
As in the first approach, the addition of sugar moieties 
was used to increase hydrophilicity and improve 
pharmacokinetic properties. Approach 3: A click- 
chemistry approach based on copper(I) catalyzed 
azide-alkyne cycloaddition (CuAAC) was used in the 
workgroup of Aboagye to prepare several [18F]fluoro-
ethyltriazole-TATE analogs of which one candidate 
was investigated in a first-in-human study [22-24]. 
Approach 4: Similarly, the click-chemistry synthesis of 
18F-fluoroglycosylated TATE was reported by 
Maschauer et al. [25]. Approach 5: In an attempt to shift 
away from the more classic prosthetic group-labeling 
approach, Laverman et al. developed a straight-
forward synthesis based on chelation of aluminum 
mono-[18F]fluoride cation ([18F]AlF2+) in 1,4,7-triaza-
cyclononae-1,4,7-triacetic acid (NOTA)-octreotide 
[26]. Approach 6: Using yet another one-step synthesis 
strategy, Wängler et al. achieved labeling of peptide 
silicon-fluoride-acceptors (SiFA) by 19F–18F isotopic 
exchange reactions (IEX) [27]. The high lipophilicity of 
the SiFA-group was later countered by the 
introduction of charged linkers, amino acids and 
sugar moieties [28, 29]. Pending the positive results of 
an ongoing toxicity assessment, the most promising 
candidate is lined up for evaluation in a 
first-in-human study [30]. Approach 7: Perrin’s group 
championed one-step 19F–18F IEX on trifluoroborates 
such as trialkylammoniomethyl-BF3 (AMBF3)-TATE 
[31, 32]. A recent addition to the field of SSTR imaging 
is the introduction of SSTR antagonists that are 
reported to have superior imaging and therapy 
properties compared to agonists despite the lack of 
probe internalization [33]. The only fluorinated 
example to date is 18F-AMBF3-LM3 [32]. Table 1 
depicts the lead candidates of all seven approaches to 
18F-labeled SSAs that represent the basis for this 
comparative review. 
Main Aspect 1: Clinical Suitability of 
18F-labeled SSA Syntheses  
A well-established and reliable synthesis 
protocol is a fundamental prerequisite for the 
development of a PET-probe and its clinical 
acceptance. In this section, the reported synthesis 
procedures for the 18F-fluorinated SSAs listed in Table 
1 are compared and evaluated from a translational 
viewpoint. The following factors are taken into 
consideration: The synthetic strategy should ideally 
allow for a fully automated probe production on a 
commercial synthesizer yielding multiple patient 
doses from a single batch of [18F]fluoride. Other 
clinical demands that should be met are an easily 
accessible (e.g. commercially available) precursor, 
minimized workload for the radiochemist, and 
reasonable overall costs for each batch production. 
From a regulatory viewpoint, the production of the 
probe must comply with current good manufacturing 
practice (cGMP)-regulations as set by the respective 
regulatory authorities, e.g., the U.S. Food and Drug 
Administration (FDA). Important denominators of a 
cGMP-conforming synthesis outcome are sufficient 
radiochemical yield (RCY), high radiochemical purity 
(RCP), high chemical purity (CP), molar activity (Am) 
appropriate for SSTR2 receptor imaging, and chemical 
stability of the formulated probe. 
Approach 1 
The key step in the synthesis of [18F]FP-Gluc- 
TOCA is the acylation of an N-(1-(4,4-dimethyl-2,6- 
dioxocyclohexylidene)ethyl) (Dde)-protected TATE- 
derivative with the prosthetic group 4-nitrophenyl 
2-[18F]fluoropropionate [17, 20]. The precursor (Nα-(1- 
deoxy-D-fructosyl)-[Lys0-Tyr3-Lys(Dde)5]-octreotate 
and the non-radioactive reference FP-Gluc-TOCA are 
commercially available (ABX Advanced Biochemical 
Compounds). For each production run, a total of five 
synthetic steps and two HPLC-purification steps are 
required. The preparation of the prosthetic group 
proceeds in three steps followed by HPLC- 
purification [34]. The following steps are acylation of 
the TATE-derivative, in situ deprotection of the 
Dde-moiety and a final HPLC-purification. The 
resulting synthesis time of about 3h is the longest of 
all 18F-labeled SSA compared here, and the overall 
workload for the radiochemist is high. Automation 
was not reported but would require non-standard 
laboratory equipment that allows for the 
implementation of five synthetic steps and two 
HPLC-purifications. RCYs range from 20% to 30% 
[17], RCP is >98%, and Am is assumed to be high since 
non-radioactive compound formed is reported to be 
below the UV-detection limit [20]. Starting activities, 
AY and CP of the formulation are not disclosed. Since 
the probe was used in first-in-human studies [18], it is 
assumed that the probe-formulation meets clinical 
requirements regarding purity, sterility, and stability. 
 Theranostics 2019, Vol. 9, Issue 5 
 
 
http://www.thno.org 
1339 
Table 1. 18F-labeled SSAs discussed in this review.  
App. Cpd. Chemical Structure IC50 [nM] Ref. 
1 [18F]FP-Gluc-TOCA 
 
SSTR1 > 10,000 
SSTR2 = 2.8±0.4 
SSTR3 > 1,000 
SSTR4 = 437±84 
SSTR5 = 123±8.8 
[17, 18] 
2 Cel-S-Dpr([18F]FBOA)TOCA 
 
SSTR1 > 1,000 
SSTR2 = 1.8±1.1 
SSTR3 = 707±30 
SSTR4 = 339±163 
SSTR5 = 45±1 
[20, 21] 
3 [18F]FET-βAG-TOCA 
 
SSTR2 = 6.9 
SSTR4 = 5.4 
[22-24] 
4 [18F]FGlc-TATE 
 
4.2 
(AR42J cells) 
[25] 
5 18F-IMP466 
 
3.6±0.6 
(AR42J cells) 
[26] 
6 [18F]SiFAlin-Glc-Asp2-PEG1-TATE 
 
14.4±1.2 
(AR42J cells) 
[28, 29] 
7 [18F]AMBF3-TATE 
 
(Ki values:) 
SSTR1 > 1,000 
SSTR2 = 0.13±0.03 
SSTR3 = 28.4±8.6 
SSTR5 = 11.6±2.8 
[31, 32] 
The 18F-moiety is attached to the N-termini of the SSA in all cases (see Figure 1). App. = Approach; Cpd = compound; IC50 = half-maximal inhibitory concentration; Ref. = 
reference. AR42J cells express high levels of the SSTR subtypes 1, 2, 3, and 5 [46].
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 Approach 2  
The synthesis of Cel-S-Dpr([18F]FBOA)TOCA 
consists of the production of 4-[18F]fluorobenzalde-
hyde ([18F]FBA) and subsequent oxime formation 
with an aminooxy-functionalized TATE-derivative 
that is not commercially available [20, 21]. The 
one-step production of [18F]FBA is well established on 
various commercial synthesizers and only requires 
cartridge-purification. The oxime-formation proceeds 
in a single step under pH-controlled conditions and 
produces the final probe in a RCY-range of 40% to 
60% within 50 minutes after HPLC-purification. Only 
110 nmol of the peptide precursor are required 
thereby reducing overall costs. Although automation 
was not reported, its implementation should be 
straightforward with minor changes to the protocol to 
avoid the addition of small reagent volumes, which is 
challenging on most commercial radiosynthesizers. 
As for [18F]FP-Gluc-TOCA, RCP is >98%, and Am is 
estimated to be high. AY is not disclosed, but 
automated multidose production of Cel-S-Dpr([18F] 
FBOA)TOCA from high doses of [18F]FBA is 
conceivable [35]. 
Approach 3 
[18F]FET-βAG-TOCA is synthesized in a two- 
step process that comprises the formation of 1-azido- 
[18F]fluoroethane ([18F]FEA) followed by copper(I)- 
catalyzed azide-alkyne cycloaddition (CuAAC) with 
the peptide precursor (4 mg per run; obtained under 
contract from ABX Advanced Biochemical Compou-
nds) [24]. [18F]FEA is purified by distillation, which is 
not a standard operation on most commercial 
synthesizers and might require customization as well 
as the implementation of safety precautions for 
processing of volatile radioactive compounds. The 
final product is purified by HPLC. A disposable 
cassette that allows for full automation of the process 
on a FASTlab synthesizer (GE Healthcare), including 
the distillation step, was developed (U.S. Patent 
20140097078 A1). [18F]FET-βAG-TOCA is obtained in 
non-decay-corrected RCY of 6.2% ± 2.9% within 100 
minutes. RCP is reported to be 100%, and Am is 
observed in a range of 224 to 562 GBq/µmol. AY or 
staring activities are not disclosed, but the mean 
administered activity was 156 ± 8 MBq. Quality 
control is performed according to European 
Pharmacopoeia guidelines. 
Approach 4 
The production of [18F]FGlc-TATE is conducted 
following a three-step, two-pot protocol [25, 36]. The 
prosthetic group 6-deoxy-6-[18F]fluoroglucosyl azide 
is synthesized in two steps and requires HPLC- 
purification of the intermediate product. The final 
product is formed via CuAAC between the prosthetic 
group and the peptide precursor followed by a second 
HPLC-purification. The peptide precursor is not 
commercially available but exhibits structural 
similarities to the alkyne-TATE derivative from 
Approach 3. The manual protocol includes small- 
volume additions of crucial reagents (~10 µL) that are 
difficult to implement on certain synthesizers and 
therefore requires modifications. As in the case of 
Approach 1, the automation of two HPLC-purifications 
per single production-run is non-standard and 
warrants special laboratory equipment. [18F]FGlc- 
TATE is obtained in non-decay-corrected RCY of 
19%–22% within 70 minutes and Am in the range of 
32-106 GBq/µmol. AY of 95-110 MBq from 500 MBq of 
[18F]fluoride are reported, but neither RCP nor CP is 
disclosed. 
Approach 5 
18F-IMP466 is synthesized by the chelation of 
[18F]AlF2+ with NOTA-conjugated octreotide and 
represents the only 18F-labeled SSA prepared by this 
method [26]. [18F]AlF2+ is produced by reacting 
[18F]KF with AlCl3 under controlled pH-conditions. 
The reaction of [18F]AlF2+ with the custom-made 
precursor leads to the formation of the final product 
which is purified by HPLC. The synthesis was 
performed manually starting with 2–6 GBq of 
[18F]fluoride. Automated synthesis of a different 
[18F]AlF-labeled peptide in AY of up to 30 GBq was 
reported elsewhere [37]. 18F-IMP466 is obtained in 
50% RCY within 45 minutes and Am of 45 GBq/µmol. 
After purification, two inseparable radioactive 
peptide peaks are observed, indicating the formation 
of two stereoisomers. Based on analytical HPLC, free 
[18F]AlF2+ is found to be absent in the final 
formulation, and CP is estimated to be high. 
Approach 6 
[18F]SiFAlin-Glc-Asp2-PEG1-TATE is prepared by 
applying a manual 19F-by-18F-IEX protocol [28]. Only 
25 nmol of the custom-made peptide precursor are 
used per run. For the synthesis, [18F]fluoride is 
activated by aqueous-free elution from a strong 
anion-exchange cartridge using a complex consisting 
of cryptand 222 and KOH [38]. For the IEX to proceed 
in satisfactory yields, the strongly basic mixture needs 
to be partially neutralized by the addition of a precise 
amount of oxalic acid. A cartridge-based workup 
yields the final product in RCY of 49.8% ± 5.9% (n = 
20) within 20–25 minutes. RCP is ≥98%, and Am is 
observed in a range of 44–63 GBq/µmol when starting 
from 3.3–6.7 GBq of [18F]fluoride. Notably, in IEX the 
precursor is inseparable from the labeled product, and 
higher AY is therefore linked to increased Am. Since 
 Theranostics 2019, Vol. 9, Issue 5 
 
 
http://www.thno.org 
1341 
the authors were aiming at a kit-like production 
protocol, automation of the procedure that would 
allow for the production of higher AY is not 
described. The crucial neutralization step requires 
precise additions of small oxalic-acid volumes, which 
complicates automation of the procedure on certain 
synthesizers. By using commonly-used azeotropic- 
drying protocols, the neutralization step is made 
obsolete thereby facilitating automation [27]. 
Approach 7 
[18F]AMBF3-TATE is synthesized by an IEX 
protocol from a custom-made peptide precursor [31]. 
The operations of the manual procedure are 
performed remotely from outside the hot cell, which 
allows for using starting activities of up to 37 GBq. 
The AMBF3-TATE precursor (50 nmol) in pyridazine- 
HCl buffer (pH=2) is reacted with aqueous 
[18F]fluoride at elevated temperature followed by a 
cartridge-based workup yielding the final product in 
injectable form. The procedure yields more than 7.4 
GBq of [18F]AMBF3-TATE from 29.6–37 GBq of 
[18F]fluoride within 25 minutes (decay-corrected RCY 
> 30%). RCP is >99%, and Am is reported to be >111 
GBq/µmol. Full automation of the protocol on 
common synthesizers will require adjustment of 
reagent volumes but is feasible, since uncommon 
operations are not involved. 
Which approach is most suitable for clinical 
production?  
Seven different synthetic approaches to 
18F-labeled SSA were investigated for their clinical 
suitability. Approaches 1 to 4 rely on established 
prosthetic group strategies that require multiple steps, 
whereas Approaches 5 to 7 are one-step procedures that 
potentially expedite the production of the injectable 
probe. Within the prosthetic-group category, the 
synthesis of Cel-S-Dpr([18F]FBOA)TOCA (Approach 2) 
stands out owing to its straightforward two-step- 
strategy that does not require specialized laboratory 
equipment and appears to be implementable on a 
wide array of commercially available synthesizers. 
Overall synthesis time is short, the involved steps are 
well established, and the production of the injectable 
probe in high AY is conceivable. In the one-step 
reaction category, the production of [18F]AMBF3- 
TATE (Approach 7) is achieved by applying the most 
straightforward synthesis protocol in the entire field. 
High AY of the injectable probe can be produced in 
only 25 minutes, which minimizes the workload for 
the radiochemist. Associated costs are low since no 
expensive reagents are required, and only low 
amounts of the precursor are used. Another 
prerequisite for the usefulness of the 18F-labeled SSA 
analogs is their stability in the final product 
formulation over an extended period of time and at 
high activity concentrations. At present, there is no 
stability data available for the approaches 
summarized in this review; however, it is likely that 
all probes will exhibit at least sufficient stability for 
imaging studies. The addition of radical scavengers 
and pH adjustments can potentially secure the 
long-term stability to allow the safe distribution of 
probes to even far distant sites [39]. Overall, the 
synthesis of [18F]AMBF3-TATE appears to be most 
suitable for the clinical production of 18F-labeled SSA. 
Main Aspect 2: Preclinical Imaging 
Performance of 18F-labeled SSAs 
Along with the clinical suitability of the probe 
synthesis, the demonstration of satisfactory in vivo 
imaging properties is a vital denominator in the 
search for an 18F-labeled SSA for clinical translation. 
The seven approaches to 18F-labeled SSAs are 
reviewed with focus on the following desired in vivo 
properties: Rapid and sufficient uptake of the probe 
into tumor lesions; Fast clearance from non-target 
organs to allow for imaging shortly after injection; 
High target-to-background ratio for efficient detection 
of metastatic lesions; Minimal physiological uptake in 
target organs to reduce interference with the lesion 
identification in those organs; And sufficient probe 
stability against undesired metabolism, decompose-
tion, and defluorination (i.e. loss of labeling tag).  
Approach 1 
Compared to its non-carbohydrated predecessor 
(2-[18F]fluoropropionyl-D-phe1)-octreotide) which sh-
owed low tumor uptake and retention and unfavora-
ble biokinetics in rodents [15, 16], [18F]FP-Gluc- 
TOCA demonstrates more favorable biodistribution 
in both AR42J tumor-bearing mice as well as CA20948 
tumor-bearing rats [17]. The probe accumulates in the 
tumor with a percent injected dose per gram tissue 
(%ID/g) of 13.5 ± 1.47 peaking at around 1 h post 
injection (p.i.). The predominant renal clearance 
results in a high uptake in the kidney (8.69 ± 1.09 
%ID/g) and a low tumor-to-kidney ratio of 1.56. All 
other organs demonstrate sufficiently high tumor-to- 
non-tumor organ ratios. With %ID/g of 0.72 ± 0.14, 
the uptake in the liver, an organ with frequent NET 
metastases, is lower than that of other probes such as 
the non-carbohydrated (2-[18F]fluoropropionyl-D- 
phe1)-octreotide)[17]. (2-[18F]Fluoropropionyl-D-phe1 
)-octreotide exhibits a liver uptake of 11.1 ± 4.6 %ID/g 
in non-tumor bearing NMRI mice, demonstrating the 
stark impact of the hydrophilic carbohydrate-moiety 
on the biodistribution. The stability of [18F]FP-Gluc- 
TOCA towards defluorination is adequate as reflected 
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by a low bone uptake of 0.7 ± 1.47 %ID/g and a 
tumor-to-bone ratio of 20. 
Approach 2  
In contrast to the promising pharmacokinetic 
properties of [18F]FP-Gluc-TOCA (Approach 1) stands 
its time-consuming and low-yielding synthesis. To 
improve the synthesis aspect while keeping the 
apparent pharmacokinetic benefits of the carbohydra-
tion, Wester et al. developed the probe Cel-S-Dpr 
([18F]FBOA)TOCA which benefits from a fast and 
high-yielding 18F-labeling via oxime formation. 
Compared to other probes in the field, Cel-S-Dpr 
([18F]FBOA)TOCA exhibits the highest tumor uptake 
of 24.04 ± 2.54 %ID/g at 1 h p.i in AR42J tumor 
bearing mice [20]. At this time-point, fast tumor 
uptake and a favorable renal clearance result in a high 
tumor-to-kidney ratio of 3.21. Similar to [18F]FP-Gluc- 
TOCA, liver uptake is low (0.88 ± 0.12 %ID/g). The 
comparably low uptake in non-target organs leads to 
promising tumor-to-organ ratios of 27, 200, and 28 for 
liver, muscle, and bone, respectively. A low femur 
uptake of 0.64 ± 0.04 %ID/g suggests good in vivo 
stability of the probe towards defluorination.  
Approach 3 
[18F]F-FET-βAG-TOCA, the most clinically 
advanced 18F-labeled SSA probe in the field, was 
selected from a series of similar compounds due to its 
favorable pharmacokinetic properties [22]. In pre- 
clinical investigations, the derivative [18F]F-FET-G- 
TOCA showed the highest absolute tumor uptake 
(17.05 ± 2.77 %ID/g), but the derivative comprising 
the βAG linker showed a lower background uptake 
while maintaining a sufficient tumor uptake of 11.58 ± 
0.67 %ID/g. It was therefore chosen as the lead. 
Further characteristics of the probe are a kidney 
uptake of about 25 %ID/g accompanied by fast renal 
clearance. [18F]F-FET-βAG-TOCA appears to be stable 
in plasma as demonstrated by the lack of other 
metabolites in the radio-HPLC trace of mouse plasma 
collected 30 min p.i.. Uptake in the liver is low and in 
vivo stability against defluorination was confirmed by 
negligible bone uptake. In a head to head comparison 
with [68Ga]Ga-DOTA-TATE, tumor uptake of 
[18F]F-FET-βAG-TOCA was found to be higher at the 
important 1 h p.i. timepoint [22]. 
Approach 4 
Similarly to [18F]FP-Gluc-TOCA and Cel-S-Dpr 
([18F]FBOA)TOCA, [18F]FGlc-TATE also features a 
carbohydrate moiety to aid the pharmacokinetic 
profile, but in this case the carbohydrate also contains 
the 18F-label. Tumor uptake of [18F]FGlc-TATE peaks 
around 30 min at %ID/g of 7.87 ± 1.11 in AR42J tumor 
bearing mice; earlier than most other probes 
compared here. In combination with the comparably 
rapid renal clearance (9.0 %ID/g at 30 min p.i.; 3.4 
%ID/g at 60 min p.i.; 0.8 %ID/g at 120 min p.i.), the 
kinetic profile of this probe potentially allows for an 
earlier imaging post tracer injection, thereby reducing 
the duration of stay for patients in the clinic [25]. At 1 
h p.i., the time point at which tumor uptake of most 
other probes peaks, tumor uptake of [18F]FGlc-TATE 
has decreased to 5.62 ± 1.63%ID/g. Non-target organ 
uptake values at 1 h p.i. are low (0.91 ± 0.25 %ID/g, 
0.46 ± 0.78 %ID/g, and 0.58 ± 0.34 %ID/g for liver, 
muscle, and femur, respectively). Notably, the 
comparatively low tumor uptake causes the 
tumor-to-organ ratios to remain only moderate at 1.6, 
6.2, 12.2 and 9.7 for kidney, liver, muscle and bone, 
respectively. 
Approach 5 
The chemical structure 18F-IMP466 resembles 
that of other radiometal-containing probes including 
[68Ga]Ga-DOTA-TATE. Despite the structural unique-
ness of 18F-IMP466 among the 18F-labeled SSAs 
compared here, its biodistribution properties are not 
remarkably different to the rest of the field. The probe 
exhibits a noticeably high tumor uptake of 28.3 ± 5.2 
%ID/g 2 h p.i. in an AR42J mouse model [40]. Comp-
ared to its 68Ga-labeled counterpart, 68Ga-IMP466 
exhibits a lower kidney retention of about 10% ID/g, 
which is nevertheless higher than that of other 
18F-labeled SSAs. The bone uptake is negligible (0.33 ± 
0.07 %ID/g 2 h p.i.), demonstrating the chemical 
stability of the [18F]AlF2+-chelation. In comparison, 
injection of free [18F]AlF2+ results in a bone uptake of 
36.9 ± 5 %ID/g. The tumor uptake of 18F-IMP466 in 
mouse models was compared to that of [18F]F-FET- 
βAG-TOCA (Approach 3) and shown to be similar at 
the 1 h p.i. time-point [22]. 
Approach 6 
[18F]SiFAlin-Glc-Asp2-PEG1-TATE exhibits impr-
oved pharmacokinetic properties compared to 
previous SiFA-TATE derivatives which suffered from 
high liver uptake caused by the high lipophilicity of 
the SiFA-moiety [27]. This is achieved by combining 
the positively charged SiFAlin building block with 
hydrophilic aspartate residues as well as carbohydra-
tion. The probe [18F]SiFAlin-Glc-Asp2-PEG1-TATE 
was compared head-to-head with [68Ga]Ga-DOTA- 
TATE, giving valuable insight into how 18F-labeled 
SSAs compare to their radiometal counterparts. In an 
AR42J mouse model, [18F]SiFAlin-Glc-Asp2-PEG1- 
TATE shows a higher tumor uptake (18.51 ± 4.89 
%ID/g) vs. that of [68Ga]Ga-DOTA-TATE (14.1 ± 4.84 
%ID/g) at 1 h p.i. However, the latter has a lower 
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uptake in non-tumor organs giving it a higher 
tumor-to-background ratio resulting in higher quality 
PET images [28]. In vivo bone uptake was measured to 
be 1.31 ± 0.31 %ID/g at 90 min p.i., which is slightly 
higher than the bone uptake of other 18F-labeled SSAs. 
Approach 7 
In an AR42J mouse model, [18F]AMBF3-TATE 
exhibits fast tumor uptake that plateaus around 30 
min p.i. which resembles the kinetic characteristic of 
[18F]FGlc-TATE (Approach 4). PET images at 60 min 
p.i. show rapid elimination of the probe through the 
kidneys and accumulation in the bladder [31]. 
Hepatobiliary excretion causes tracer accumulation in 
the gut and the gallbladder. The clearance from 
non-target organs is fast, leading to high tumor-to- 
non-tumor organ ratios of 26.2 ± 0.8, 25.1 ± 1.0, 
89.0 ± 3.1, and 21.3 ± 3.6 for liver, blood, muscle, and 
bone, respectively. [18F]AMBF3-TATE shows sufficient 
metabolic stability over the investigated time course 
of up to 120 min as determined by plasma stability 
measurements with radio-HPLC.  
Which approach shows the most promising 
imaging performance in the pre-clinical 
setting?  
All 18F-labeled SSAs reviewed here demonstrate 
favorable in vivo imaging properties in the AR42J 
mouse model. Overall, the probes show high tumor 
uptake, fast, primarily renal, clearance, and low 
non-target organ uptake. An overview of published 
organ uptake values is listed in Table 2. Where not 
originally included, tumor-to-organ ratios were 
calculated based on available data. At 1 h p.i., 
Cel-S-Dpr([18F]FBOA)TOCA (Approach 2) displays the 
highest tumor uptake of 24.04 ± 2.54 %ID/g, whereas 
18F-IMP466 (Approach 5) shows the highest uptake of 
28.3 ± 5.2 %ID/g at 2 h p.i.. Taking into account the 
higher tumor-to-kidney ratio of Cel-S-Dpr([18F]FBOA) 
TOCA, the probe appears to be an attractive candidate 
for clinical translation. Other than the extent of tumor 
uptake, a rapid accumulation of PET-probes in the 
target tissue is a desired feature from a patient 
management perspective, since it decreases the period 
of stay for patients in the nuclear medicine facility. 
The available data shows that [18F]FGlc-TATE 
(Approach 4) and [18F]AMBF3-TATE (Approach 7) show 
faster tumor uptakes than the other probes. Tumor 
accumulation for these probes plateaus around 30 min 
p.i. as opposed to 1 h p.i. for other probes. Since the 
tumor uptake of [18F]AMBF3-TATE is higher than that 
of [18F]FGlc-TATE, Approach 7 appears to be a suitable 
candidate for clinical translation if early imaging post 
injection is desired. A better comparison of imaging 
performances in vivo is hampered by the lack of direct 
comparisons with the clinical standard [68Ga]Ga- 
DOTA-TATE for most of the 18F-labeled SSAs. 
Without this direct comparison to a known reference 
standard, inter-laboratory variability cannot be 
readily quantified although it is generally regarded to 
be significant. The absolute values as presented in 
Table 2 should, therefore, be taken with caution. 
Unfortunately, none of the probes were tested in a 
more clinically relevant metastatic mouse model of 
NETs. 
Main Aspect 3: First Clinical Experiences 
With 18F-labeled SSAs 
Three of the probes reviewed herein, [18F]FP- 
Gluc-TOCA (Approach 1), [18F]F-FET-βAG-TOCA 
(Approach 3), and 18F-IMP466 (Approach 5) are 
currently being evaluated in early clinical trials. A 
phase I/II trial for 18F-IMP466 (NCT03511768) is at an 
early stage as of the time of writing and limited data is 
available. These first in-human studies give valuable 
insight regarding the clinical validity of 18F-labeled 
SSAs for imaging of NETs. In the following section, 
the available data is summarized with a focus on the 
comparison between the imaging properties of 
18F-labeled SSAs and other clinically established PET 
probes. 
 
Table 2. Summary of preclinical biodistribution data of the seven approaches compared to the current gold standard 
[68Ga]Ga-DOTA-TATE. 
App. Compound Time Point Tumor 
[%ID/g] 
Bone 
[%ID/g] 
Tumor/ Kidney Tumor/ Liver Tumor/ Muscle Tumor/ Bone Ref. 
1 [18F]FP-Gluc-TOCA 1h 13.54 0.68 1.56 19 56 20 [17] 
2 Cel-S-Dpr([18F]FBOA)TOCA 1h 24.04 0.64 3.21 27 200 38 [20] 
3 [18F]FET-βAG-TOCA 1h 11.58 -  -  - 24.12  - [22] 
4 [18F]FGlc-TATE 1h 5.62 0.58 1.64 6.2 12 9.7 [25] 
5 18F-IMP466 2h 28.3 0.33 2.83 - - 86 [26] 
1h 12.73 - - - 37.44 - [22] 
6 [18F]SiFAlin-Glc-Asp2-PEG1-TATE 1h 18.51 1.31 (1.5h)  1.21 (65m)  8.97 (65m) 39.35 (65m) - [28, 29] 
7 [18F]AMBF3-TATE 1h 10.11 0.46 2.06 26 92 22 [31] 
- [68Ga]Ga DOTATATE 1h 24.1 - 6.2 48 80 - [47] 
1h 1.37 - - - 2.28 - [22] 
1h 14.1 - - - - - [28] 
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Approach 1 
In a comparative study in humans, [18F]FP-Gluc- 
TOCA was evaluated against OctreoScan [18]. [18F]FP- 
Gluc-TOCA shows high uptake in metastatic lesions 
in the liver and fast blood clearance, predominantly 
by renal clearance but also by hepatobiliary transport 
as shown by the late time point uptake in the 
gallbladder. The tumor-to-non-tumor contrast is high 
which allows for clear delineation of the liver lesions 
as opposed to OctreoScan. Superiority of [18F]FP- 
Gluc-TOCA over OctreoScan is confirmed by the 
detection of more than double the number of lesions. 
Predominant factors for this superiority are the 
technical advantages of PET over SPECT such as 
increased spatial resolution, noise reduction, and 
attenuation correction.  
Approach 3 
In a first-in-human study, [18F]F-FET-βAG- 
TOCA shows high uptake in tumor lesions and a 
favorable tumor-to-background contrast [24]. The 
tumor-to-background ratio in the liver is similar to 
that of previously reported values for 68Ga-labeled 
probes. The probe shows fast uptake into the tumor 
(<1 h) and clears rapidly from non-target organs, 
except for the gallbladder due to increased 
hepatobiliary excretion over time. No bone uptake is 
observed, confirming stability against defluorination 
in vivo. In a first report from a phase I clinical trial 
(EudraCT number 2013-003152-20) comparing 
[18F]F-FET-βAG-TOCA with [68Ga]Ga-DOTA-TATE in 
32 patients diagnosed with NETs as per ENETS 
criteria, [18F]F-FET-βAG-TOCA was shown to have 
higher sensitivity (92.8% vs 87.5%) and detect more 
lesions (209 vs 197 lesions) compared to [68Ga]Ga- 
DOTA-TATE. [18F]F-FET-βAG-TOCA detected additi-
onal bone and lymph node lesions in three of the 
patients. In addition, [18F]F-FET-βAG-TOCA was safe 
and well-tolerated in the patients [41].  
Approach 5 
The safety profile of 18F-IMP466 was studied in 
three healthy volunteers and was well tolerated. 
18F-IMP466 shows physiological uptake in pituitary, 
thyroid, liver, spleen, adrenals, pancreatic uncinate 
process, stomach, as well as small and large bowel. It 
is primarily excreted through the kidney but also 
partially through the gallbladder [42]. In a study 
comparing [18F]FDG and 18F-IMP466 in twelve 
neuroendocrine neoplasms (NENs) patients (three 
grade 1, four grade 2, and five grade 3), it showed 
higher maximum standardized uptake value (SUVmax) 
in grade 1 and 2 patients, but a lower SUVmax in grade 
3 patients. Among the twelve first patients, 
18F-IMP466 detected lesions in eleven patients (92%) 
whereas [18F]FDG only detected lesions in eight of the 
patients (66%). Although the patient number in this 
study is low, a similar trend was found in other 
comparison studies between [68Ga]Ga-DOTA-TATE 
and [18F]FDG [43, 44]. 18F-IMP466 had a higher uptake 
in grade 1 and 2 patients as opposed to [18F]FDG 
which had higher uptake in grade 3 patients. This is 
similar to [68Ga]Ga-DOTA-TATE which also shows 
higher uptake than [18F]FDG in lower-grade tumors 
and lower uptake in higher-grade tumors. Unfortun-
ately, no comparative SST2 evaluation of 18F-IMP466 
to OctreoScan or [68Ga]Ga-DOTA-TATE was included 
in this study. 
Are 18F-labeled probes a viable alternative to 
[68Ga]Ga-DOTA-TATE in clinical studies? 
First-in-human studies are a critical first step 
towards initiating phase I/II clinical trials and 
ultimately getting the probes approved for routine 
clinical service. For clinical approval, 18F-labeled SSAs 
need to be safe and tolerable, have favorable 
biodistribution characteristics, and demonstrate high 
lesion detection rates. To compete with [68Ga]Ga- 
DOTA-TATE in routine clinical care, 18F-labeled SSAs 
should have similar, preferably higher, lesion 
detection rates.  
The 18F-labeled SSAs currently translated into 
humans are all safe and tolerable. Whereas the tumor 
uptakes and biodistribution of [18F]FP-Gluc-TOCA, 
18F-IMP466, and [18F]F-FET-βAG-TOCA resemble that 
of [68Ga]Ga-DOTA-TATE, the 18F-labeled probes show 
an increased uptake in the gallbladder due to a more 
prevalent biliary excretion. However, we do not 
expect this to be detrimental to lesion detection. The 
tumor-to-background ratios in the liver of 
[18F]FP-Gluc-TOCA and [18F]F-FET-βAG-TOCA are 
4.2 ± 2 and 4.3 ± 2.69, respectively, and, therefore, 
higher than that of [68Ga]Ga-DOTA-TATE (2.0; 
interquartile range 1.4–2.7) [45]. No data is currently 
publicly available for 18F-IMP466. [18F]F-FET-βAG- 
TOCA, the only 18F-labeled SSA compared head-to- 
head with [68Ga]Ga-DOTA-TATE to date, shows a 
higher lesion detection rate. Taken together, the 
available clinical data suggests that 18F-labeled SSAs 
are a clinically viable alternative to [68Ga]Ga-DOTA- 
TATE.  
Epilog 
The ever-increasing understanding of 
underlying mechanisms in oncology has led to the 
development of non-invasive diagnostic PET-probes 
that have become indispensable in clinical patient 
care. Among those diagnostic probes, [18F]FDG, a 
probe assessing abnormal glucose metabolism, is the 
most commonly used. However, [18F]FDG is not well 
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suited for imaging tumors with low glycolytic activity 
and therefore there is a need for the development of 
specific, targeted PET-probes in oncology. SST2 is a 
well-established target for imaging and therapy of 
NETs. The development and extensive study of the 
SST receptor targeting peptides NOC, TOC and TATE 
eventually led to market approval of [68Ga]Ga-DOTA- 
TATE (Netspot®) and [177Lu]Lu-DOTA-TATE (Luta-
thera®) for diagnosis and treatment of NETs, 
respectively. 
Due to the increased demand of 68Ga-labeled 
PET-probes on the one hand, and difficulties in 
meeting the supply with 68Ge/68Ga-generators on the 
other, the clinical introduction of 18F-labeled SSAs has 
become a necessity. Although it has been proposed 
that theranostic pairs should ideally consist of 
chemically identical compounds (i.e. compounds that 
only differ by the chelated radiometal), this paradigm 
is being questioned. In the case of the theranostic pair 
[177Lu]Lu-DOTA-TATE and [68Ga]Ga-DOTA-TATE, 
for example, diagnostic imaging essentially helps 
localizing the exact sites of subsequent treatment with 
the therapeutic agent. In this case, dosimetry could 
arguably help to individualize treatment activity 
levels. However, in clinical routine, many patients 
treated with [177Lu]Lu-DOTA-TATE are often 
diagnosed using structurally different imaging probes 
such as 111In-labeled OctreoScan, [68Ga]Ga-DOTA- 
TOC, or [68Ga]Ga-DOTA-NOC and treatment activity 
levels are mostly defined based on kidney and liver 
function assays. Another prominent theranostic pair 
that consists of structurally different compounds are 
the imaging probe [68Ga]Ga-PSMA-11 and the 
therapeutic agent [177Lu]Lu-PSMA-617 used for 
treatment of patients with metastatic, castration- 
resistant prostate cancer. Prediction of treatment 
outcome using diagnostic imaging has been shown to 
be difficult and the evidence suggests that 
PET-imaging will likely not contribute significantly to 
prognosis. The most important criteria that can be 
assessed by imaging for treatment planning is the 
evaluation of target expression. Arguably, any 
diagnostic probe with suitable pharmacokinetic 
properties as well as high affinity and selectivity for 
the same target as the therapeutic compound can be 
used for that. We, therefore, expect that the 18F-labeled 
SSAs compared here will be suitable for this task. 
However, among the numerous published 
options, most 18F-labeled SSAs have not yet been 
evaluated in humans and no candidate has been 
evaluated in a prospective phase II/III trial so far. 
In an effort to select the candidates that have the 
potential to become a widely used routine SST2 PET 
imaging agent, we have summarized the current state 
of the art. Considering all available data, which 
compound should be chosen to undergo the clinical 
development process? The probes compared herein 
all exhibit high binding affinities to SSTR2 and 
perform well in preclinical imaging studies. With the 
highest tumor uptake at 1 h p.i. and a favorable 
tumor-to-kidney ratio, Cel-S-Dpr([18F]FBOA)TOCA 
performed exceptionally well in a preclinical setting. 
If an earlier time-point for imaging is desired, 
[18F]AMBF3-TATE stands out with the highest tumor 
uptake at 30 min p.i.  
The similar characteristics of the various 
18F-labeled probes in preclinical investigations adds 
importance to the synthesis aspect. A successful 
18F-labeled SSA candidate will have to feature a cheap, 
straightforward, and reliable synthesis procedure that 
requires no dedicated equipment or specialized 
process experience. The synthesis of Cel-S-Dpr 
([18F]FBOA)TOCA meets most of these requirements 
and should be amenable to implement on commercial 
synthesis modules without much efforts. Although 
standard equipment in most radiopharmacies, 
expensive laboratory equipment such as the 
radiosynthesizer and HPLC equipment are required. 
[18F]AMBF3-TATE on the other hand can be produced 
in high RCY and Am in a single step and does not 
require HPLC purification. Taking into account its 
favorable pharmacokinetic properties that potentially 
allows for imaging at earlier time-points p.i., a 
widespread acceptance of the probe in clinical patient 
care is conceivable.  
In the reality of a nowadays highly regulated 
probe development cycle, scientific considerations are 
not the only driving force in establishing a diagnostic 
probe as the standard of care. Despite its more 
challenging production characteristics and slightly 
inferior imaging properties in preclinical studies, 
[18F]F-FET-βAG-TOCA currently is the most clinically 
advanced probe in the field; A fact that must be 
attributed to the remarkable efforts of the scientists 
and caregivers involved in its development. The 
probe has shown promising results in a phase I trial 
including 32 patients [41]. These efforts are crucial 
since they underline the feasibility of applying 
18F-labeled SSAs in patients. It remains to be seen if an 
agreement on the future standard of care will be 
reached based on practical assumptions or a 
dedicated research consortium making the case for 
their respective approach. In any way, the 
development of 18F-labeled SSAs will be of benefit to 
the patients since it will reduce costs and increase the 
availability of probes. More patients will benefit from 
the theranostic approach towards the state of the art 
treatment of NETs. 
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